Optimizing Early-Stage Commercial Assessments for Emerging Biopharma

A guide to sizing commercial assessments at each stage of asset development, from early exploration through detailed decision modeling, for emerging biopharma navigating limited resources and high-stakes funding decisions.

Overview

Emerging biopharma now accounts for the majority of clinical trial starts and originates more than half of new drug launches, but smaller companies face a recurring challenge: securing the funding needed to advance assets without the resources of large pharma. We outline how commercial assessments, from early exploration through detailed decision modeling, can be sized to the asset’s stage and the precision required by the decision. The paper details research and forecast structures appropriate at each phase, the role of target product profile testing, and how risk-adjusted NPV supports the deal modeling that underpins partnerships and transactions.

Key Takeaways

• Commercial assessments should be right-sized to the asset’s stage, with research scope and forecast complexity matched to the available clinical information
• Clinical profile uncertainty is the largest source of risk in early-stage assessments, so over-investing in large primary research samples rarely improves the answer
• A credible early-stage forecast is one that articulates a range of outcomes alongside a clear value story, since deals are arrangements for sharing risk